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Abstract
Our genetic background provides limited information on individual risk of developing 
vascular complications overtime. New biological layers, namely epigenetic modifications, 
are now emerging as potent regulators of gene expression thus leading to altered 
transcriptional programs and vascular disease phenotypes. Such epigenetic modifications, 
defined as changes to the genome that do not involve changes in DNA sequence, are 
generally induced by environmental factors and poor lifestyle habits. Of note, adverse 
epigenetic signals acquired during life can be transmitted to the offspring thus leading to 
premature alterations of the epigenetic and transcriptional landscape eventually leading 
to early endothelial dysfunction and vascular senescence. Modifications of the epigenome 
play a pivotal role in the pathophysiology of cardiometabolic disturbances such as obesity 
and type 2 diabetes. In these patients, changes of DNA methylation and chromatin 
structure contribute to alter pathways regulating insulin sensitivity, glucose homeostasis, 
adipogenesis and vascular function. In this perspective, unveiling the ‘epigenetic landscape’ 
in cardiometabolic patients may help to identify new players implicated in obesity and 
diabetes-related vascular dysfunction and may pave the way for personalized therapies in 
this setting. In the present review, we discuss current knowledge of the epigenetic routes 
implicated in vascular damage and cardiovascular disease in patients with metabolic 
alterations.
Cardiovascular disease burden in people 
with diabetes
Cardiovascular diseases (CVD) are the main cause of death 
and disability among patients with obesity and type 2 
diabetes mellitus (T2DM). By the year 2035, more than 
650 million will have impaired glucose tolerance and 
592 million people will have diabetes worldwide (1). A 
recent study analysing data from 6,264,226 adults (18 
years of age or older) who participated in the Behavioral 
Risk Factor Surveillance System Survey (1993–1994 and 
1999–2016) showed that by 2030 nearly 1 in 2 US adults 
will have obesity with a prevalence ranging from 35 to 
50% (2). Moreover, nearly 1 in 4 adults is projected to 
have severe obesity by 2030 and the prevalence will be 
higher than 25% in most of US states (2). Taken together, 
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and severe obesity will continue to increase in the decades 
to come. These numbers have strong implications on 
morbidity and mortality as patients presenting with 
cardiometabolic alterations are several-fold more likely 
to develop myocardial infarction and stroke than age-
matched subjects without this condition (3). Alterations 
occurring in patients with obesity and diabetes, 
namely insulin resistance, defective insulin secretion, 
low-grade inflammation foster the development of 
endothelial dysfunction, increased platelet reactivity, 
and pro-thrombotic states – all factors contributing to 
atherosclerotic vascular disease and CV events (4). Albeit 
therapeutic strategies have been significantly implemented 
over the last decade, residual risk remains high in 
this patient population. By this background, a better 
understanding of the intersection between maladaptive 
metabolic processes and CVD is of paramount importance 
to identify new targets and design breakthrough therapies 
in this growing patient population.
Epigenetic regulation of gene expression
Accumulating evidence suggests that the ‘non-genetic’ 
regulation of vascular function is gaining increasing 
attention. Studies conducted over the last 2 decades have 
contributed to unmask the pivotal role of epigenetic 
changes in the regulation of gene expression (5). Epigenetic 
modifications are plastic chemical changes of DNA 
and histone proteins which have the ability to modify 
the activity of DNA, without affecting the nucleotide 
sequence (6). This change in DNA activity leads to a fine-
tuning regulation of gene transcription. In other words, 
epigenetics represents an additional layer of biological 
regulation which, together with the genetic information, 
modulates gene expression trajectories over the lifetime 
(7, 8). Several lines of evidence support the fundamental 
and independent role of epigenetic regulation. For 
example, genetically identical pluripotent stem cells 
differentiate towards specific cell lines (i.e, fibroblasts, 
myocytes) thanks to specific epigenetic changes occurring 
at given time points (7). Similarly, monozygotic twins 
– who share an identical genetic makeup - display high 
discordance rates for common diseases (i.e. asthma), 
and this phenomenon is explained by epigenetic 
modifications (9, 10). Epigenetic regulation is a complex 
process which often requires the cooperation of different 
signals (DNA methylation, histone modifications, 
and ncRNAs) acting in concert (5). DNA methylation 
and histone modifications take place at the level of 
chromatin, whereas ncRNAs mostly act indirectly at the 
posttranslational level. However, recent evidence suggests 
that ncRNAs may directly regulate chromatin accessibility 
by regulating nucleosome positioning, DNA methylation 
and activity of chromatin remodelers (11). The mechanism 
by which epigenetic changes modify DNA activity is via 
regulation of chromatin structure. The latter may assume 
two different states: packed in a dense structure which 
is inaccessible for transcription (heterochromatin) or in 
a looser, uncondensed and open for transcription state 
(euchromatin) (12). Dynamic changes of chromatin 
architecture critically modulate gene transcription by 
regulating the binding of transcription factors to DNA.
DNA methylation
DNA methylation is a well-studied epigenetic 
modification which consists in a covalent modification 
mainly occurring at cytosines followed by guanines (ie, 
CpG dinucleotides) to form 5-methylcytosine (6). In most 
cases, methylation of DNA is a process repressing gene 
transcription. This occurs by hampering the recruitment 
of transcription factors or by fostering transcriptional 
silencing (5). The repression of transposons repeats 
and the X-chromosome inactivation represent valid 
examples of how DNA methylation changes control gene 
expression (13). Different families of enzymes, known as 
DNA methyltransferases (DNMTs), participate in DNA 
methylation. DNMT1 is responsible for the maintenance 
of methylation, whereas DNMT3a and DNMT3b mediate 
de novo methylation of DNA (14). DNA methylation is 
a reversible modification that can be removed either 
passively, by reduced activity of DNMT1, or actively, by 
the ten-eleven translocation enzymes (TETs).
Histone modifications
Together with DNA methylation, chemical modifications 
of histones (acetylation, methylation, ubiquitination, 
phosphorylation, sumoylation, citrullination, and 
ADP-ribosylation) are critically involved in chromatin 
remodelling and regulation of gene expression (15). 
The regulation of chromatin accessibility by histone 
modifications is highly complex due to the diversity of 
modifications and their different biological function. 
Indeed, the net effect on gene transcription really depends 
on the type of modification and on the position of the 
modified amino acid residue (6). Histone acetylation is 
mediated by histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) and is generally associated with an 
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open chromatin and enhanced gene transcription. By 
contrast, histone methylation may impact differently on 
gene transcription based on which amino residue is being 
modified. Histone methyltransferases (HMTs) catalyze the 
transfer of a methyl group from S-adenosyl-L-methionine 
to lysine or arginine residues in a highly specific manner 
(6). Recently, the discovery of histone demethylases 
(HDMs) increased the complexity of gene regulation 
by making histone methylation a dynamic rather than 
a static process. Of note, modifications of histone tail 
may affect DNA methylation (and vice versa) thus 
amplifying the complexity of epigenetic regulation (12). 
A known example of this interaction is represented by the 
cross-talk between H3K9 methylation and DNA 
methylation to repress gene expression in a specific 
chromatin region (16, 17).
Non-coding RNAs
NcRNAs are RNA molecules which are not transcribed 
into proteins but regulate gene expression at the 
posttranslational level by interacting with mRNA. 
Recent evidence indicates that ncRNAs also regulate the 
expression of enzymes involved in chromatin remodeling 
(18). Based on size, ncRNAs can be subdivided into 
two major groups: (i) small ncRNAs (sncRNAs, <200 
nucleotides long) including miRNA, PIWI-interacting 
RNAs, and endogenous short interfering RNAs and (ii) 
long ncRNAs (lncRNAs), which have a length between 0.2 
kb and 2 kb (19).
Epigenetic modifications and cardiovascular 
damage in obesity and diabetes
Insulin resistance, adiposity and 
endothelial dysfunction
Several studies have shown that epigenetic modifications 
are responsible for several pathological changes 
observed in patients with obesity and T2DM (Fig. 1). 
Environmental factors such as pollution, urban noise 
and cigarette smoking are potent inducers of epigenetic 
changes (20). Once acquired, these modifications 
contribute to derail pathways implicated in the 
regulation of adipogenesis, low-grade inflammation, 
liver steatosis and endothelial dysfunction (21). Most 
importantly, epigenetic alterations are being transmitted 
across multiple generations thus leading to altered gene 
expression patterns during childhood and adolescence 
(22). The transgenerational inheritance of epigenetic 
Figure 1
Main epigenetic modifications in the cardiometabolic patient. H3, histone 3; K, lysine residue. IL-6, interleukin-6; MCP-1, monocyte chemoattractant 
protein-1; NF-kB, nuclear factor kappa-B; eNOS, endothelial nitric oxide synthase.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/VB-20-0001
https://vb.bioscientifica.com © 2020 The authors
 Published by Bioscientifica Ltd
S Costantino et al. Epigenetics and vascular 
function
H222:1
https://vb.bioscientifica.com © 2020 The authors
 Published by Bioscientifica Ltd
signals may certainly contribute to the epidemic of 
childhood obesity and the increase in CV risk observed in 
these subjects (23). One out of four obese children shows 
a detrimental cluster of cardiovascular risk factors which 
leads to a 10-fold increase in the risk of CVD as compared 
to non-obese children (24). Epigenetic tags on the 
promoter of TNF-alpha (TNFα), pyruvate dehydrogenase 
kinase 4 (PDK4), leptin (LEP), peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α) 
and proopiomelanocortin (POMC) were found to be 
inherited and causally implicated in the development of 
metabolic and cardiovascular disease (25, 26).
In patients with obesity and T2DM, epigenetic 
modifications participate to the progressive loss of insulin 
sensitivity eventually leading to dysglycemia, micro- and 
macrovascular complications (27). Patients with obesity 
display altered methylation patterns of genes controlling 
insulin signalling, namely COL9A1, IGF2BP1, ZNF714, 
ADCY9 and TBX5 (28). Specifically, ZNF714 was found 
to be the gene with the largest methylation fold-change 
among insulin resistant and insulin sensitive patients. 
Hypomethylation of the zinc finger protein 714 (ZNF714) 
promoter was associated with higher gene expression 
in insulin-resistant patients (28). Modifications of the 
epigenetic landscape also control the expression of 
genes involved in vascular insulin resistance, a major 
determinant of systemic loss of insulin sensitivity. DNA 
methylation and ncRNAs have indeed shown to modulate 
key pathways, namely the PCKβ/p66Shc, NOX2 and 
NF-kB, strongly implicated in oxidative stress generation 
and inflammation eventually fostering the impairment 
of vascular insulin sensitivity (29, 30). The progressive 
impairment of endothelial cell function due to ROS 
accumulation and reduced NO bioavailability also leads 
to defective capillary recruitment and hampered insulin 
delivery to hormone sensitive organs. Hence, deregulation 
of specific vascular pathways by epigenetic modifications 
may be responsible for systemic metabolic changes thus 
favouring the development of prediabetes and type 2 
diabetes (31). In visceral fat arteries from patients with 
obesity and insulin resistance, a complex chromatin 
network characterized by the demethylase SUV39H1, 
the methyltransferase JMJD2C and the acetyltransferase 
SRC-1 was found to be causally involved in the 
generation of vascular oxidative stress and endothelial 
dysfunction. Targeting these chromatin enzymes 
was indeed able to rescue obesity-related endothelial 
dysfunction, thus highlighting the potential relevance of 
chromatin modifications in the pathogenesis of vascular 
complications (32).
Epigenetic pathways of vascular damage in diabetes
In patients with diabetes, high blood glucose levels 
contribute to affect the epigenetic landscape thus 
leading to persistent deregulation of genes controlling 
vascular homeostasis. Indeed, hyperglycaemia was 
found to induce long-lasting transcriptional alterations 
in the cardiovascular system (4, 33). Such bad legacy of 
hyperglycemia - mediated by epigenetic changes – may 
help to explain the lack of benefit of intensive glycemic 
control on macrovascular complications and mortality 
in DM patients. Indeed, intensive glycemic control 
strategies recently failed to reduce the rate of myocardial 
infarction, stroke and cardiovascular mortality among 
patients with T2DM (34, 35, 36). This phenomenon 
– defined ‘hyperglycemic memory’ – indicates a long-
term persistence of hyperglycemic stress even after 
blood glucose normalization (37). Several studies have 
demonstrated the detrimental impact of persistent 
transcriptional changes induced by high glucose levels. 
Fibroblasts isolated from patients with diabetic foot ulcers 
displayed a persistent demethylation of genes critical 
to wound repair, angiogenesis, and extracellular matrix 
assembly. Noteworthy, such gene-related methylation 
patterns persisted in patient-derived fibroblasts after 
prolonged passage in normoglycemic conditions, 
thus demonstrating the existence of a transcriptional 
memory driven by hyperglycemia (38). Along the same 
line, experiments in primary human endothelial cells 
showed that hyperglycemia reduces DNA methylation 
at the promoter of the mitochondrial adaptor p66Shc, a 
key protein involved in cytochrome c oxidation and 
accumulation of free radicals (39). Reduced methylation 
of p66Shc promoter and increased H3 acetylation – known 
activating epigenetic marks - were associated with gene 
upregulation, mitochondrial oxidative stress and impaired 
availability of nitric oxide, eventually leading to vascular 
dysfunction. Of note, restoration of normoglycemia was 
not able to erase the activating marks and this explained 
persistent transcription of p66Shc and persistent ROS 
production in the vasculature. Interestingly, blockade of 
critical enzymes involved in chromatin remodeling such 
as the acetyltransferase GCN5 reduced H3 acetylation 
on p66Shc promoter thus restoring physiological p66Shc 
expression and endothelial function (40). These 
epigenetic networks were found to be operative also in 
humans as intensive glycemic control for 6 months was 
not able to reduce epigenetic changes of p66Shc promoter 
in patients with T2DM (41). Other epigenetic networks 
driven by SIRT1 were found to be responsible for the 
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vascular complications of diabetes. Specifically, SIRT1 
overexpression prevents endothelial dysfunction by 
suppressing NF-κB activation and PARP cleavage while 
restoring hyperglycemia-induced dephosphorylation of 
LKB1 and AMP kinase (AMPK), two critical regulators of 
energy balance (42). Interestingly, SIRT1 was also found 
to modulate p66Shc and p53 in the diabetic vasculature 
as well as in stem cells from diabetic mice (43, 44, 45). 
Another activating epigenetic mark, namely acetylation 
of lysine 9 at histone 3 (H3K9), plays a pivotal role in the 
pathogenesis of diabetes-related vascular inflammation. 
Indeed, hyperglycemia-induced H3K9 acetylation was 
found to promote inflammatory transcriptional programs 
in vascular smooth muscle cells (VSMCs) isolated from 
T2DM mice as well as in lymphocytes from type 1 diabetic 
(T1DM) patients (44, 46). Mono-methylation at lysine 4 
of histone 3 (H3K4m), induced by the methyltranfsrease 
SETD7, also represents a relevant chromatin signature 
favouring the expression of genes implicated in 
endothelial inflammation and oxidative stress (47, 48, 
49, 50, 51). SETD7 activation is particularly relevant in 
the setting of diabetes where it is responsible for the 
upregulation of nuclear factor kappa-B (NF-kB) subunit 
p65 and subsequent transcription of NF-kB inflammatory 
genes such as VCAM-1 and ICAM-1 (49). Of clinical 
relevance, SETD7 is upregulated in peripheral blood 
monocytes from patients with T2DM, and significantly 
correlates with NF-kB p65-driven inflammation, 
oxidative stress and endothelial dysfunction (50). 
Interestingly, this methyltransferase is amenable of 
pharmacological intervention, with several compounds 
already available (52).
microRNAs and cardiovascular damage in obesity 
and diabetes
Together with DNA methylation and histone marks, 
ncRNAs are critically involved in obesity and diabetes-
related cardiovascular damage. Several miRNAs, including 
miR-320b, miR-29b, miR-1, miR-133a and miR-499 were 
found to be involved in the persistence of myocardial 
damage despite intensive glycemic control (53). Targeting 
these miRNAs, which are actively involved in myocardial 
fibrosis, hypertrophic growth, oxidative stress and 
autophagic response, may represent a potential strategy 
to prevent diabetic cardiomyopathy and heart failure (53). 
Along the same line, miR-34 and miR-218 were found to 
play a pivotal role in the diabetic heart (29). Specifically, 
miR-34 and miR-218 – respectively targeting deacetylase 
SIRT1 and methyltransferase DNMT3b - were found 
to be upstream regulators of chromatin accessibility, 
leading to persistent upregulation of oxidant genes 
despite restoration of normoglycemia (29). Zhong   et  al. 
have shown that several miRNAs persistently derail 
transcriptional programs in the vascular endothelium. 
In particular, miR-125b, miR-146a-5p, and miR-29a-3p 
– respectively targeting inflammatory cytokines TNF-α-
induced protein 3 (TNFAIP3), TNF receptor-associated 
factor 6 (TRAF6) and IL-1 receptor (IL-1R) – were 
associated with a persistent impairment of endothelial 
function and altered expression of proinflammatory 
genes (54). Direct inhibition of miR-125b or miR-
146a-5p overexpression blunted NF-kB-related signals 
and improved endothelial function (54). A further study 
showed that restoration of normoglycemia was not able to 
blunt miR-23b-3p upregulation in retinal endothelial cells, 
and this contributed to diabetic retinopathy through a 
SIRT1/NF-kB signalling pathway (55). In patients with 
T2DM, the expression of miR-326 – a direct modulator 
of adiponectin and adiponectin receptors (ADIPOR)-1, 
ADIPOR-2 - was elevated and negatively correlated with 
adiponectin levels. Of note, miR-326 upregulation was not 
affected by 12-months of antidiabetic treatment, suggesting 
its contributions to cardiometabolic disturbances, even in 
the presence of target HbA1c levels (56).
The emerging role of long non-coding RNAs
A growing body of evidence suggests the involvement 
of lncRNAs in the pathogenesis of vascular disease in 
conditions of metabolic stress (57). In a systematic 
transcriptional screening, Singh and colleagues found that 
out of 30,586 lncRNAs screened, 100 were upregulated 
and 186 downregulated in HUVECs cultured under high 
as compared to normal glucose conditions (58). Similarly, 
microarray analysis performed in lymphatic endothelial 
cells from diabetic and non-diabetic patients showed 
significant variations induced by hyperglycemia, with 31 
lncRNAs downregulated and 79 lncRNAs upregulated (59). 
Among these signatures, several well-known lncRNAs 
were found, including H19, GAS5, UCA1, CRNDE, GAS5, 
and LINC00312. Interestingly, network analysis showed 
that these lncRNAs may be related to insulin reporter 
signalling pathway and response to insulin stimulus (59).
The lncRNA metastasis-associated lung 
adenocarcinoma transcript 1 (MALAT1) was found to be 
elevated during the early stages of high glucose stimulation 
in HUVECs, and this alteration was associated with a 
parallel increase in serum amyloid antigen 3 (SAA3), as 
well as with other pro-inflammatory cytokines such as 
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/VB-20-0001
https://vb.bioscientifica.com © 2020 The authors
 Published by Bioscientifica Ltd
S Costantino et al. Epigenetics and vascular 
function
H242:1
https://vb.bioscientifica.com © 2020 The authors
 Published by Bioscientifica Ltd
TNF-α and IL-6. Of note, these alterations were prevented 
by silencing of MALAT1 (60). A recent study showed that 
MALAT1 expression was increased in an experimental 
mouse model of type 2 diabetes and positively correlated 
with HOMA-IR and resistin levels (61). In line with these 
findings, MALAT1 siRNA attenuated resistin, Ang II and 
inflammatory molecules, whereas it enhanced glucose 
uptake and nitric oxide production (NO). The authors also 
showed that exercise was able to downregulate MALAT1 
with subsequent reduction of resistin levels (61). In line 
with these findings, Malat1-knockout T1DM animals were 
protected against hyperglycemia-induced elevations of 
inflammatory markers (62).
RNCR3 lncRNA has been shown to play a role in T2DM-
induced retinal microvascular dysfunction through the 
RNCR3/KLF2/miR-185-5p axis (63). Activation of the latter 
pathway was also found to protect against atherosclerotic 
vascular disease. Indeed, in mouse and human aortic 
atherosclerotic lesions, as well as cultured HUVECs 
and VSMCs exposed to high ox-LDL concentrations, 
RNCR3 depletion accelerated atherosclerosis, aggravated 
hypercholesterolemia and vascular inflammation while 
decreasing cell proliferation and migration (64).
The lncRNA called myocardial infarction–associated 
transcript (MIAT) was also shown to be upregulated 
in the retina of diabetic rats as well as upon ambient 
hyperglycemia in cultured endothelial cells. In vitro studies 
revealed that MIAT knockdown ameliorated diabetes 
mellitus-induced retinal microvascular dysfunction by 
inhibiting endothelial cell proliferation, migration, and 
tube formation (65). LncRNA Maternally expressed gene 
3 (MEG3) has been shown to be protective in diabetes-
related endothelial dysfunction via activation of PI3k/
Akt signalling . MEG3 expression was reduced retinas of 
STZ-induced diabetic mice and in high glucose-exposed 
endothelial cells. In experimental mouse models, 
knockdown of MEG3 was associated with increased 
number of a cellular capillaries, increased vascular leakage, 
and increased inflammatory markers such as interleukins, 
TNF-α, and CCL2 (66). MEG3 knockdown was also 
associated with exacerbation of inflammatory damage, 
induction of cell proliferation and suppression of apoptosis 
in glucose-treated HUVECs. Mechanistic studies revealed 
that regulation of the apoptotic pathways was associated 
with upregulation of BCL-2 and downregulation of BAX, 
caspase-3, and p53, whereas the proliferation processes 
were related with activation of TGF-β and Wnt/β-catenin 
pathways (67). In diabetic rats, overexpression of the 
lncRNA ANRIL promoted Vegf upregulation and increased 
angiogenesis via activation of NF-κB signalling (68). A 
recent study also demonstrated that knocking down 
ANRIL, MALAT1, and ZFAS1 prevented glucose-induced 
upregulation of ET-1 transcripts (69).
Furthermore, a recent study demonstrated that lncRNA 
H19 is upregulated in vascular endothelium of patients 
with T2DM, where it mediates VEGFA overexpression 
via inhibition of mir-29a. Of note, H19 suppression 
significantly attenuated high glucose-induced endothelial 
inflammation and oxidative stress through VEGFA 
downregulation and AKT/eNOS pathway activation (70).
Toward personalized epigenetic therapies
Several compounds have shown their ability to target 
chromatin modifications. The unveiling of specific 
chromatin modifications has enabled the design of 
specific drugs erasing maladaptive epigenetic signals, 
thereby restoring vascular homeostasis (Table 1) (27). 
Activators of histone deacetylases have shown to 
Table 1 Available compounds to target chromatin modifications for the prevention of obesity and diabetes-induced vascular 
dysfunction.
References Therapy Main finding
Zhang  et al. (57, 58), 
Xia  et al. (59) 
Resveratrol SIRT1 inhibition attenuates adipogenesis, inflammation, oxidative stress, and 
rescues obesity-related endothelial dysfunction
Advani  et al. (61), 
Xie  et al. (62), Rafehi 
et al. (63)
Vorinostat Vorinostat regulates histone acetylation by preventing EP300/CREBBP binding at 
multiple gene promoters. It prevents eNOS uncoupling, inflammation and insulin 
signalling in adipose tissue and skeletal muscle from diabetic mice.
Hu et al. (64) Sodium butyrate Sodium butyrate suppresses NF-kB signalling and NF-kB-dependent inflammatory 
molecules. Moreover it prevents metabolic alterations in diet-induced obese as 
well as in aged mice, mainly by enhancing oxidative phosphorylation and beta-
oxidation in mitochondria.
Zhang et al. (65) Trichostatin A Trichostatin A suppresses TNF-α transcription in the context of ischemia-induced 
left ventricular remodeling.
Tsujikawa et al. (67), Ray 
et al. (68)
Apabetalone Prevents vascular inflammation by modulating the transcription of VCAM-1, ICAM-1, 
TNFα and IL1-beta
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repress transcription of genes participating to vascular 
oxidative stress and inflammation. Specifically, the SIRT1 
activator resveratrol has demonstrated to prevent eNOS 
uncoupling and to suppress obesity and hyperglycemia-
induced inflammation by inhibition of NF-kB signalling 
pathway as well as NF-kB-related cytokines such as TNFα 
(44, 71). SIRT1 activation also modulates adipogenesis 
and function of perivascular adipose tissue, a major 
determinant of vascular health (72). The translation of 
these experimental findings to humans has yielded to 
conflicting results and ongoing clinical trials will help 
to clarify whether SIRT1 activators may be employed in 
the clinical setting to prevent cardiometabolic alterations 
(73). Other histone deacetylase inhibitors such as 
vorinostat and thrichostatin A shown beneficial effects in 
preventing endothelial dysfunction, ischemia/reperfusion 
injury and diabetic nephropathy (74, 75, 76). Apabetalone 
(development codes RVX 208, RVX-208, and RVX000222) 
a small molecule targeting bromodomain and extra 
terminal domain (BET) proteins (in particular the BET 
family member), also represent a promising drug given 
its ability to modulate gene transcription by preventing 
the interaction of histones with DNA (77). Of interest, 
Apabetalone was shown to prevent the upregulation of 
IL-1β, IL-6 and TNF-α in human endothelial cells exposed 
to high glucose levels as well as in aortic plaques from 
ApoE-/- mice (78). However, the recent BETonMACE trial 
failed to show a clear cardiovascular benefit of apabetalone 
in patients with diabetes and a recent acute coronary 
syndrome. However, data from secondary endpoints are 
promising and larger clinical trials are needed in this 
regard (79). Given the explosion of the new anti-diabetic 
therapies with glucagon-like peptide-1 receptor agonists 
(GLP-1 RA) and sodium glucose cotransporter 2 inhibitors 
(SGLT2i) (80), a plenty of recent studies appearing in 
rapid succession started to investigate the mechanisms 
underlying their cardiovascular benefits. Interestingly, 
GLP-1 RA were shown to modulate the expression of 
miRNA-338, thus restoring pancreatic β-cell function 
and glucose homeostasis (81). Other studies showed that 
GLP1 RA control liver steatosis – a key cardiometabolic 
risk factor - by regulating the hepatic expression of 
miRNA-34a, miRNA-21 and miRNA-200b/c (82). Along 
the same line, the SGLT2i empagliflozin was recently 
found to modulate hyperglycemia-induced microvascular 
oxidative stress by modulating the p38 MAPK/miR-21 
pathway (83). This finding is interesting as recent work has 
shown that improvement of microvascular function by 
SGLT2i reduces myocardial inflammation and oxidative 
stress (84), important features contributing to heart failure 
development in people with diabetes (85). Although these 
studies raise significant interest, more research is needed 
to appraise how new glucose-lowering drugs induce 
changes of miRNA landscape, and whether these changes 
are causally implicated in the disease development.
Evidence discussed so far suggests that epigenetic 
therapies are able to interfere with chromatin structure and 
miRNAs, and may represent a new frontier in cardiovascular 
medicine. There remain, however, important evidence 
gaps to be considered before moving to the clinical 
setting. First, many drugs targeting chromatin modifiers 
are not specific as they also implicated in the regulation 
of other pathways. Second, the safety of this approach 
remains to be proven. Indeed, these compounds may 
not selectively erase methylation or acetylation signals in 
specific cells, this may lead to unspecific and undesirable 
modulation of transcriptional programs. Third, the 
epigenetic landscape is extremely diverse according 
to different organs and we currently lack epigenetic 
biomarkers reflecting chromatin modifications in specific 
tissues (vasculature, heart). Single-cell RNA sequencing 
approaches will help to decipher the epigenetic repertoire 
of different cells with the aim of developing more targeted 
approaches. The complexity of epigenetic information 
may significantly contribute to explain why patients with 
the same disease (obesity) display different vascular risk 
trajectories overtime. In this respect, understanding the 
individual epigenetic regulation may open perspectives 
for personalized therapies to combat obesity and type 2 
diabetes in the decades to come.
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